ChemedFRA:CXM +1.04%75 Interest Coverage is 165.15 as of Mar. 2026, which is 78% above its 10-year median of 93.03. GuruFocus rates FRA:CXM with a GF Score™ of 75/100 and a GF Value™ of €566.42 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 453 Healthcare Providers & Services companies, Chemed ranks better than 87.2% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Chemed's
Operating Income
for the
three
months ended in Mar. 2026 was €73 Mil. Chemed's Interest Expense for the
three
months ended in Mar. 2026 was €-0 Mil.
Chemed's interest coverage for the quarter that ended in Mar. 2026 was 165.15.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Chemed's Interest Coverage or its related term are showing as below:
FRA:CXM'
s Interest Coverage Range Over the Past 10 Years
Min: 47.73 Med: 93.03 Max: 206.15
Current: 171.22
FRA:CXM's Interest Coverage is ranked better than 87.2% of 453
companies
in the Healthcare Providers & Services industry
Industry Median: 7.98
vs FRA:CXM: 171.22
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Chemed Interest Coverage Related Terms
Chemed Interest Coverage Historical Data
* Premium members only.
The historical data trend for Chemed's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:CXM vs PACS, OPCH, CON: Interest Coverage Comparison
For the Medical Care Facilities subindustry, Chemed's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed Interest Coverage vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Chemed's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemed (FRA:CXM) has a Interest Coverage of 165.15 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chemed and its competitors. This is 78% above median its historical median of 93.03. Over the past decade, Chemed's Interest Coverage has ranged from 47.73 to 206.15. According to the industry distribution chart, Chemed ranks #58 out of 453 companies in the Healthcare Providers & Services industry, placing it in the top 12.8%.
Is Chemed's Interest Coverage too high?
Chemed's current Interest Coverage of 165.15 is 78% above median its 10-year median of 93.03. Over the past 10 years, this metric has ranged from a low of 47.73 to a high of 206.15. The Healthcare Providers & Services industry median Interest Coverage is 7.98. Chemed's value of 165.15 is 1969.5% above this industry median. Based on the distribution chart, Chemed ranks #58 out of 453 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chemed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Interest Coverage compare to PACS and OPCH?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #58 out of 453 companies for Interest Coverage. This places Chemed in the top 13% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 7.98. Chemed's value of 165.15 is 1969.5% above this benchmark. Historically, Chemed's own Interest Coverage has ranged from 47.73 to 206.15 over the past decade. While the company's 10-year median is 93.03 vs. the industry median of 7.98, Chemed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Healthcare Providers & Services company?
The median Interest Coverage among Healthcare Providers & Services companies is 7.98, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current Interest Coverage of 165.15 is 1969.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median Interest Coverage is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current Interest Coverage is 165.15, which is 78% above median its own 10-year median of 93.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €566.42, compared to a current price of €390.00 — trading 31.1% below its estimated fair value. The current Interest Coverage is 165.15, which is 78% above median its 10-year median of 93.03 and 1969.5% above the Healthcare Providers & Services industry median of 7.98. Chemed's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Interest Coverage is 165.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €390.00 is trading 31.1% below its estimated GF Value™ of €566.42.
GuruFocus considers Chemed to be Significantly Undervalued.
Key valuation signals for FRA:CXM:
Interest Coverage: 165.15 (78% above median its 10-year median of 93.03)
GF Value™: €566.42 vs. price of €390.00 (31.1% below fair value)
Industry Position: 1969.5% above the Healthcare Providers & Services median (#58 of 453)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
75GF Score
Get the complete analysis for FRA:CXM
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
